143 related articles for article (PubMed ID: 21094428)
21. Linezolid in vitro: mechanism and antibacterial spectrum.
Livermore DM
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii9-16. PubMed ID: 12730138
[TBL] [Abstract][Full Text] [Related]
22. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
[TBL] [Abstract][Full Text] [Related]
23. In-vitro activity of linezolid against clinical isolates of Gram-positive cocci in a tertiary care hospital.
Navaneeth BV; Belwadi SM; Indumathi VA; Gayathri DD
J Assoc Physicians India; 2004 May; 52():429-30. PubMed ID: 15656039
[No Abstract] [Full Text] [Related]
24. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.
Mendes RE; Deshpande LM; Jones RN
Drug Resist Updat; 2014 Apr; 17(1-2):1-12. PubMed ID: 24880801
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, China.
Tian Y; Li T; Zhu Y; Wang B; Zou X; Li M
BMC Microbiol; 2014 Nov; 14():292. PubMed ID: 25420718
[TBL] [Abstract][Full Text] [Related]
26. Linezolid, the first oxazolidinone antibacterial agent.
Leach KL; Brickner SJ; Noe MC; Miller PF
Ann N Y Acad Sci; 2011 Mar; 1222():49-54. PubMed ID: 21434942
[TBL] [Abstract][Full Text] [Related]
27. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid.
Wareham DW; Abbas H; Karcher AM; Das SS
J Infect; 2006 Apr; 52(4):300-4. PubMed ID: 16099052
[TBL] [Abstract][Full Text] [Related]
28. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program.
Mutnick AH; Enne V; Jones RN
Ann Pharmacother; 2003 Jun; 37(6):769-74. PubMed ID: 12773059
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial resistance to linezolid.
Meka VG; Gold HS
Clin Infect Dis; 2004 Oct; 39(7):1010-5. PubMed ID: 15472854
[TBL] [Abstract][Full Text] [Related]
30. In vitro susceptibility of staphylococci to linezolid and other antimicrobial agents.
Poiată A; Tuchiluş C; Bădicuţ I; Grigore L; Buiuc D
Roum Arch Microbiol Immunol; 2002; 61(4):293-9. PubMed ID: 15055263
[TBL] [Abstract][Full Text] [Related]
31. Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.
Sahm DF; Deane J; Bien PA; Locke JB; Zuill DE; Shaw KJ; Bartizal KF
Diagn Microbiol Infect Dis; 2015 Feb; 81(2):112-8. PubMed ID: 25488274
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
Borbone S; Lupo A; Mezzatesta ML; Campanile F; Santagati M; Stefani S
Int J Antimicrob Agents; 2008 Mar; 31(3):209-15. PubMed ID: 17646087
[TBL] [Abstract][Full Text] [Related]
33. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.
Chien JW; Kucia ML; Salata RA
Clin Infect Dis; 2000 Jan; 30(1):146-51. PubMed ID: 10619743
[TBL] [Abstract][Full Text] [Related]
34. [New treatment option for gram-positive infections in critically ill patients - overview over linezolid].
Krueger WA; Unertl KE
Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Apr; 37(4):199-204. PubMed ID: 11967745
[TBL] [Abstract][Full Text] [Related]
35. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
37. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.
Morales G; Picazo JJ; Baos E; Candel FJ; Arribi A; Peláez B; Andrade R; de la Torre MA; Fereres J; Sánchez-García M
Clin Infect Dis; 2010 Mar; 50(6):821-5. PubMed ID: 20144045
[TBL] [Abstract][Full Text] [Related]
38. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains].
Efe S; Sinirtaş M; Ozakin C
Mikrobiyol Bul; 2009 Oct; 43(4):639-43. PubMed ID: 20084917
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
Sader HS; Streit JM; Fritsche TR; Jones RN
Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
[TBL] [Abstract][Full Text] [Related]
40. Use of linezolid in pediatrics: a critical review.
Dotis J; Iosifidis E; Ioannidou M; Roilides E
Int J Infect Dis; 2010 Aug; 14(8):e638-48. PubMed ID: 20106697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
